Answers are grounded in this paper and cite their sources.
Gene therapy demonstrates potential for curative treatment in sickle cell disease, suggesting wider accessibility for patients.
Sickle cell disease is one of the most common genetic diseases worldwide. Clinical manifestations include pain, inflammation, organ damage, and shortened life span. Until recently, the only treatment with curative intent was stem cell transplantation; however, this treatment requires a human leukocyte antigen–matched bone marrow donor. In December 2023, two types of autologous gene therapy were approved by the U.S. Food and Drug Administration, bringing the option for treatment with curative intent to all patients, not just those with donors. These treatments are complex, costly, and time-consuming, and they require clinician expertise, but for patients who need them, they can be transformative.At a GlanceOncology nurses often care for patients with sickle cell disease in their practice settings.Supportive care for patients undergoing gene therapy is similar to that for those undergoing stem cell transplantation and requires an interprofessional approach.Novel gene therapy is an exciting, potentially transformative treatment with complex and challenging processes for insurance authorization and treatment logistics.
No takes yet. Share an insight, caveat, or question.
Elana Smilow (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: